<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081755</url>
  </required_header>
  <id_info>
    <org_study_id>013-307</org_study_id>
    <nct_id>NCT02081755</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer</brief_title>
  <official_title>A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective Phase IV study to determine if the use of Everolimus results in&#xD;
      lower liver tumor recurrence and improved patient and graft survival after liver transplant&#xD;
      for hepatocellular carcinoma (HCC). The immunosuppressive comparators will be Everolimus and&#xD;
      Tacrolimus therapy compared to Tacrolimus and Mycophenolic acid/Mycophenolate&#xD;
      Mofetil/Azathioprine. Primary outcomes data is disease free survival (the time from&#xD;
      randomization to HCC recurrence or death). Secondary outcomes are rate of recurrence of&#xD;
      Hepatitis C, problems related to wound healing, hernia repair within the first 12 months,&#xD;
      hepatic arterial thrombosis, renal function, acute cellular rejection, post-transplant&#xD;
      diabetes, hypertension, and hyperlipidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will consist of approximately 336 patients (224 Everolimus and&#xD;
      Tacrolimus and 112 Tacrolimus and Mycophenolic acid/Mycophenolate Mofetil/Azathioprine).&#xD;
      Initial screening criteria will include the presence of hepatocellular carcinoma in patients&#xD;
      18 years or older who are candidates to receive a primary orthotopic liver transplant (from&#xD;
      deceased or living donor). Within 7 - 12 days post-transplant, patients will be re-evaluated&#xD;
      for eligibility for randomization. The criteria include: pre-transplant imaging that shows&#xD;
      HCC disease exceeding Milan criteria; pathology review for tumor burden and/or presence of&#xD;
      microvascular invasion; AFP &gt;200IU/mL; pre-transplant ablation or resection with HCC&#xD;
      recurrence; progression or new tumors; evaluation to rule out any hepatic vessel&#xD;
      complication.&#xD;
&#xD;
      Subjects will remain in study treatment until Month 12 at which time the subject and&#xD;
      investigator will determine the preferred immunosuppressive regimen. Subjects will be&#xD;
      followed for an additional 24 months for outcome data as described above.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS) defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first.</measure>
    <time_frame>Through Month 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor recurrence sites</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis C recurrence rate</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute cellular rejection</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-transplant diabetes</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperlipidemia</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing and associated risk factors</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hernia repair</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic arterial thrombosis</measure>
    <time_frame>Through Month 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Everolimus and Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus Dosing: 1.5 mg BID (3.0 mg/day) Tacrolimus Dosing: 0.05 mg/kg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus and Myfortic or CellCept or Imuran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Myfortic: 360 mg to 1080 mg BID OR CellCept: 500 mg to 1500 mg BID OR Imuran: 0.5mk/kg to 2mg/kg QD AND Tacrolimus Dosing: 0.05 mg/kg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months</description>
    <arm_group_label>Everolimus and Tacrolimus</arm_group_label>
    <other_name>Zortress</other_name>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus Dosing: 0.05 mg/kg BID for 12 months</description>
    <arm_group_label>Everolimus and Tacrolimus</arm_group_label>
    <arm_group_label>Tacrolimus and Myfortic or CellCept or Imuran</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic</intervention_name>
    <description>Myfortic®: 360 mg to 1080 mg BID for 12 months</description>
    <arm_group_label>Tacrolimus and Myfortic or CellCept or Imuran</arm_group_label>
    <other_name>Mycophenolic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CellCept</intervention_name>
    <description>CellCept: 500 mg to 1500 mg BID for 12 months</description>
    <arm_group_label>Tacrolimus and Myfortic or CellCept or Imuran</arm_group_label>
    <other_name>Mycophenolate Mofetil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imuran</intervention_name>
    <description>0.5 mg/kg to 2 mg/kg QD for 12 months</description>
    <arm_group_label>Tacrolimus and Myfortic or CellCept or Imuran</arm_group_label>
    <other_name>Azathioprine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of hepatocellular carcinoma (HCC) and high risk for HCC recurrence&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
          -  Male and female patients of any race, 18 years or older&#xD;
&#xD;
          -  De novo recipients of a primary orthotopic liver transplant from a deceased or living&#xD;
             donor&#xD;
&#xD;
          -  Patients willing to comply with study requirements&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) must agree to use an effective method(s) of&#xD;
             contraception during treatment and during the post treatment follow-up period&#xD;
&#xD;
        Screening Exclusion Criteria:&#xD;
&#xD;
          -  Past or present malignancy within the last 5 years.&#xD;
&#xD;
          -  Severe infection considered by the local site investigator to be unsafe for study&#xD;
             participation.&#xD;
&#xD;
          -  Use of other investigational drugs at the time of screening or within the last 30&#xD;
             days.&#xD;
&#xD;
          -  Patients scheduled for a combined transplant (such as liver-kidney), or having a&#xD;
             previous solid organ, bone marrow, or autologous islet cell transplant.&#xD;
&#xD;
          -  Recipients of donor/recipient ABO incompatible grafts.&#xD;
&#xD;
          -  Recipients of organs from human immunodeficiency virus (HIV) or HBsAg positive donors.&#xD;
&#xD;
          -  Macrovascular tumor invasion.&#xD;
&#xD;
          -  Proteinuria greater than 2 grams/24 hours.&#xD;
&#xD;
          -  Conditions which can result in impaired absorption, distribution, metabolism or&#xD;
             excretion of the study treatment.&#xD;
&#xD;
          -  Patients with non-infectious pneumonitis.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive human chorionic gonadotropin (hCG) laboratory test.&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) not practicing an effective method(s) of&#xD;
             contraception.&#xD;
&#xD;
          -  Patients who receive sirolimus (Rapamune®) as part of their transplant&#xD;
             immunosuppression regimen&#xD;
&#xD;
        Randomization Screening Inclusion Criteria :&#xD;
&#xD;
        - For patients with a history of any hepatic vessel thrombosis, occlusion, stent placement,&#xD;
        or major revision of liver vessels, must have a Doppler ultrasound prior to randomization&#xD;
        to rule out any hepatic vessel complication, including hepatic arterial thrombosis (HAT).&#xD;
&#xD;
        Randomization Exclusion Criteria:&#xD;
&#xD;
          -  Patients who receive sirolimus (Rapamune) any time prior to randomization will be&#xD;
             withdrawn from the study.&#xD;
&#xD;
          -  Patients who develop clinically significant systemic infections requiring active use&#xD;
             of IV antibiotics any time prior to randomization.&#xD;
&#xD;
          -  Wound healing problem, per Investigator's assessment, that would make the patient&#xD;
             ineligible for study randomization&#xD;
&#xD;
          -  Confirmed presence of a thrombosis in a major hepatic artery(s), major hepatic&#xD;
             vein(s), portal vein or inferior vena cava via Doppler ultrasound or other imaging&#xD;
             obtained prior to randomization.&#xD;
&#xD;
          -  Proteinuria greater than 2 grams/24 hours.&#xD;
&#xD;
          -  Consideration by the investigator, for any reason, that the subject is an unsuitable&#xD;
             candidate to receive everolimus or be randomized into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Klintmalm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee- Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Liver Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

